Islet Transplantation in Type 1 Diabetic Kidney Allograft

PHASE2RecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 31, 2010

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Diabetes Mellitus, Type 1
Interventions
BIOLOGICAL

Allogenic islet cells (human, U. Chicago)

Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.

PROCEDURE

Intraportal infusion of islet cells

Intraportal infusion of islet cell through the portal vein in the liver.

Trial Locations (1)

60637

RECRUITING

The University of Chicago, Chicago

All Listed Sponsors
lead

University of Chicago

OTHER